What are the recommended therapeutic options for managing atopic dermatitis (eczema)?

Recommended Therapeutic Options for Atopic Dermatitis

For adults with atopic dermatitis, begin with moisturizers and topical anti-inflammatory agents (corticosteroids, calcineurin inhibitors, JAK inhibitors, or PDE-4 inhibitors), and when disease remains inadequately controlled despite optimized topical therapy or significantly impacts quality of life, advance to dupilumab as the first-line systemic agent. 1, 2

Stepwise Treatment Algorithm

Step 1: Foundation for All Patients

• Moisturizers/emollients: Strong recommendation for all severity levels 2
• Basic skin care: Appropriate bathing practices and wet wrap therapy (conditional recommendation) 2

Step 2: Topical Anti-Inflammatory Therapy

Strong recommendations for:

• Topical corticosteroids (TCS): First-line prescription treatment 2
• Topical calcineurin inhibitors (TCIs): Tacrolimus and pimecrolimus, particularly for sensitive areas without risk of cutaneous atrophy 2
• Topical JAK inhibitors: Ruxolitinib cream (recently approved, highly effective) 2, 3
• Topical PDE-4 inhibitors: Crisaborole and roflumilast cream 2, 3
• Newer agents: Tapinarof cream (strong recommendation) 3

Key topical therapy principles:

• These agents cause no cutaneous atrophy, making them suitable for long-term use and sensitive sites 4
• Consider proactive maintenance therapy: Apply mid-potency TCS or tacrolimus 2-3 times weekly to previously affected areas that rapidly recur 4
• Topical agents should be continued concurrently with systemic therapy for maintenance and flare management 1

Conditional recommendation AGAINST:

• Topical antimicrobials, antiseptics, and antihistamines 2

Step 3: Before Advancing to Systemic Therapy

Critical checkpoint when topical therapy fails:

1. Rule out alternative diagnoses: Contact dermatitis, cutaneous lymphoma 1
2. Confirm diagnosis accuracy
3. Assess treatment adherence
4. Verify topical therapy optimization
5. Evaluate quality of life impact 1

Step 4: Systemic Therapy Selection

When topical therapy is inadequate and QOL is significantly impaired:

First-Line Systemic Agent

Dupilumab (IL-4 receptor antagonist):

• Unanimous first choice among guideline workgroup members 1
• Dosing: 600 mg subcutaneously initially, then 300 mg every 2 weeks 1
• Excellent safety track record with >5 years clinical experience 1
• No laboratory monitoring required 4
• Strong recommendation 1

Alternative Systemic Options (All Strong Recommendations) 1:

JAK Inhibitors (slightly higher efficacy than dupilumab at 16 weeks, faster onset):

• Upadacitinib: Comparable efficacy to dupilumab 300 mg at 15 mg daily dose 1
• Abrocitinib: 100 mg daily somewhat less effective than dupilumab; higher doses more effective 1
• Baricitinib: Strong recommendation 1

Other Biologics:

• Tralokinumab (IL-13 antagonist): 600 mg initially, then 300 mg every 2 weeks; somewhat less effective than dupilumab at 16 weeks 1
• Lebrikizumab: Strong recommendation 3
• Nemolizumab (with concomitant topical therapy): Strong recommendation 3

Conditional Recommendations FOR:

• Phototherapy (narrowband UVB) 1
• Azathioprine 1
• Cyclosporine 1
• Methotrexate 1
• Mycophenolate 1

Conditional Recommendation AGAINST:

• Systemic corticosteroids 1

Evidence Quality and Clinical Nuances

Comparative Efficacy Insights

The 2024 AAD guidelines note that JAK inhibitors at higher doses demonstrate somewhat better efficacy than dupilumab at standard dosing, with faster onset of action 1. However, dupilumab's superior safety profile and lack of need for laboratory monitoring make it the preferred first-line choice in clinical practice 1, 4.

Common Pitfalls to Avoid

1. Premature systemic escalation: Always optimize topical therapy first and rule out alternative diagnoses 1
2. Discontinuing topicals when starting systemic therapy: Topical agents should continue for maintenance 1
3. Using systemic corticosteroids long-term: Only conditional recommendation against due to adverse effects 1
4. Overlooking phototherapy: Requires 2-3 times weekly for 10-14 weeks; accessibility is the main limitation 1

Safety Considerations

• Phototherapy: Risk of sunburn reactions and potential skin cancer (especially PUVA); less concern with narrowband UVB 1
• JAK inhibitors: Require consideration of cardiovascular and malignancy risks based on FDA warnings, though newer data continues to emerge
• Dupilumab/biologics: Minimal safety concerns in clinical trials and real-world use 1

Special Population Considerations

Dupilumab was favored as first-line by international experts for special adult populations 1, reflecting its broad applicability and safety profile across diverse patient groups.